Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P04637 (
p53
)
77,613
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The E6 protein of the high-risk human papillomaviruses (HPVs) and the cellular ubiquitin-protein ligase E6AP form a complex which causes the ubiquitination and degradation of
p53
. We show here that HPV16 E6 promotes the ubiquitination and degradation of E6AP itself. The half-life of E6AP is shorter in HPV-positive cervical cancer cells than in HPV-negative cervical cancer cells, and E6AP is stabilized in HPV-positive cancer cells when expression of the viral oncoproteins is repressed. Expression of HPV16 E6 in cells results in a threefold decrease in the half-life of transfected E6AP. E6-mediated degradation of E6AP requires (i) the binding of E6 to E6AP, (ii) the catalytic activity of E6AP, and (iii) activity of the 26S proteasome, suggesting that E6-E6AP interaction results in E6AP self-ubiquitination and degradation. In addition, both in vitro and in vivo experiments indicate that E6AP self-ubiquitination results primarily from an intramolecular transfer of ubiquitin from the active-site cysteine to one or more
lysine
residues; however, intermolecular transfer can also occur in the context of an E6-mediated E6AP multimer. Finally, we demonstrate that an E6 mutant that is able to immortalize human mammary epithelial cells but is unable to degrade
p53
retains its ability to bind and degrade E6AP, raising the possibility that E6-mediated degradation of E6AP contributes to its ability to transform mammalian cells.
...
PMID:Human papillomavirus type 16 E6 induces self-ubiquitination of the E6AP ubiquitin-protein ligase. 1086 52
DNA transcription is initiated by a small regulatory region of transactivators known as the transactivation domain. In contrast to the rapid progress made on the functional aspect of this promiscuous domain, its structural feature is still poorly characterized. Here, our multidimensional NMR study reveals that an unbound full-length
p53
transactivation domain, although similar to the recently discovered group of loosely folded proteins in that it does not have tertiary structure, is nevertheless populated by an amphipathic helix and two nascent turns. The helix is formed by residues Thr(18)-Leu(26) (Thr-Phe-Ser-Asp-Leu-Trp-
Lys
-Leu-Leu), whereas the two turns are formed by residues Met(40)-Met(44) and Asp(48)-Trp(53), respectively. It is remarkable that these local secondary structures are selectively formed by functionally critical and positionally conserved hydrophobic residues present in several acidic transactivation domains. This observation suggests that such local structures are general features of acidic transactivation domains and may represent "specificity determinants" (Ptashne, M., and Gann, A. A. F. (1997), Nature 386, 569-577) that are important for transcriptional activity.
...
PMID:Local structural elements in the mostly unstructured transcriptional activation domain of human p53. 1088 88
The adenovirus E1B 55-kDa protein binds to cellular
tumor suppressor p53
and inactivates its transcriptional transactivation function.
p53
transactivation activity is dependent upon its ability to bind to specific DNA sequences near the promoters of its target genes. It was shown recently that
p53
is acetylated by transcriptional coactivators p300, CREB bidning protein (CBP), and PCAF and that acetylation of
p53
by these proteins enhances
p53
sequence-specific DNA binding. Here we show that the E1B 55-kDa protein specifically inhibits
p53
acetylation by PCAF in vivo and in vitro, while acetylation of histones and PCAF autoacetylation is not affected. Furthermore, the DNA-binding activity of
p53
is diminished in cells expressing the E1B 55-kDa protein. PCAF binds to the E1B 55-kDa protein and to a region near the C terminus of
p53
encompassing
Lys
-320, the specific PCAF acetylation site. We further show that the E1B 55-kDa protein interferes with the physical interaction between PCAF and
p53
, suggesting that the E1B 55-kDa protein inhibits PCAF acetylase function on
p53
by preventing enzyme-substrate interaction. These results underscore the importance of
p53
acetylation for its function and suggest that inhibition of
p53
acetylation by viral oncoproteins prevent its activation, thereby contributing to viral transformation.
...
PMID:Adenovirus E1B 55-kilodalton oncoprotein inhibits p53 acetylation by PCAF. 1089 93
Mdm2 is an E3 ubiquitin ligase for the
p53 tumor suppressor protein
. We demonstrate that Mdm2 is conjugated with SUMO-1 (sumoylated) at
Lys
-446, which is located within the RING finger domain and plays a critical role in Mdm2 self-ubiquitination. Whereas mutant Mdm2(K446R) is stabilized, it elicits increased degradation of
p53
and concomitant inhibition of
p53
-mediated apoptosis. In vitro sumoylation of Mdm2 abrogates its self-ubiquitination and increases its ubiquitin ligase activity toward
p53
. Radiation caused a dose- and time-dependent decrease in the degree of Mdm2 SUMO-1 modification, which is inversely correlated with the levels of
p53
. Our results suggest that the maintenance of the intrinsic activity of a RING finger E3 ubiquitin ligase is sumoylation dependent and that reduced Mdm2 sumoylation in response to DNA damage contributes to
p53
stability.
...
PMID:SUMO-1 modification of Mdm2 prevents its self-ubiquitination and increases Mdm2 ability to ubiquitinate p53. 1220 42
Somatic mutations in the
p53 tumor suppressor
gene are the most common genetic alterations found in human malignancies. In the present study, we studied 36 primary human breast carcinomas, using a polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP) and sequencing analysis of exons 2 through 9 for the presence of
p53
gene mutations. Six of 36 (17%) breast cancers contained mutations within the core domain of the
p53 protein
responsible for sequence-specific DNA binding (codons 102-292); all 5 missense mutations clustered between codons 240 and 291 (codons 240, 243, 250, 285, and 291), whereas one nonsense mutation occurred at codon 199. By using recombinant PCR in vitro mutagenesis, we introduced point mutations at codons 199 from Gly to stop (gly199stop), 240 from Ser to Ile (ser240Ile), 250 from Pro to Ala (pro250ala), 285 from Glu to
Lys
(glu285lys), and 291 from
Lys
to Asn (lys291asn), and all the
p53
sequences were subcloned into the CMVneoBam vector under the control of the cytomegalovirus (CMV) promoter. To test whether the mutants
p53
were functionally wild-type (wt) or mutant, we transfected them to
p53
-null Saos-2 cells with a reporter plasmid containing a
p53
-responsive element, and performed chloramphenicol acetyltransferase (CAT) assay. Transient CAT assay for transcriptional activation revealed that one group, including gly199stop, ser240ile, glu285lys, and lys291asn, abolished the transcriptional activity, whereas the other group, including pro250ala, retained stronger transcriptional transactivation activity than that of wt
p53
.
...
PMID:Identification of p53 gene mutations in breast cancers and their effects on transcriptional activation function. 1090 Nov 65
The tumour suppressor
p53
induces cellular senescence in response to oncogenic signals.
p53
activity is modulated by protein stability and post-translational modification, including phosphorylation and acetylation. The mechanism of
p53
activation by oncogenes remains largely unknown. Here we report that the tumour suppressor PML regulates the
p53
response to oncogenic signals. We found that oncogenic Ras upregulates PML expression, and overexpression of PML induces senescence in a
p53
-dependent manner.
p53
is acetylated at
lysine
382 upon Ras expression, an event that is essential for its biological function. Ras induces re-localization of
p53
and the CBP acetyltransferase within the PML nuclear bodies and induces the formation of a trimeric
p53
-PML-CBP complex. Lastly, Ras-induced
p53
acetylation,
p53
-CBP complex stabilization and senescence are lost in PML-/- fibroblasts. Our data establish a link between PML and
p53
and indicate that integrity of the PML bodies is required for
p53
acetylation and senescence upon oncogene expression.
...
PMID:PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. 1091 Mar 64
Recent studies of transient focal ischemia have focused interest on apoptotic mechanisms of neuronal cell death involving constitutive pro-apoptotic proteins. The finding of specific patterns of novel gene expression might indicate the activation of pro-apoptotic genes in previously ischemic areas. Thus, we investigated gene expression for the pro-apoptotic regulators, Bax and caspase-3, after transient focal brain ischemia, together with the
p53
-regulated cell cycle inhibitor, p21/WAF1/CIP1. Reversible occlusion of the middle cerebral artery for 2 h was carried out in halothane-anesthetized rats using the poly-L-
lysine
coated filament method. In situ hybridization was performed at 0, 1, 3, 6 h and 1, 3 and 7 d of recirculation and in sham controls. Radioactive antisense probes served for detection of bax, p21 and caspase-3 mRNAs on brain sections, and quantitative film autoradiography was combined with image-averaging techniques. Bax mRNA tended to decline after focal brain ischemia within 1 d. p21 mRNA was upregulated with a perifocal pattern at 3 h and 1 d after ischemia whereas the ischemic regions themselves failed to show significant upregulation. Caspase-3 mRNA was elevated in the resistant dorsomedial cortex at 1 d. A pro-apoptotic pattern of novel gene expression, involving Bax and caspase-3, was not observed after transient focal brain ischemia. Rather, the perifocal expression of p21 and caspase-3 mRNAs observed at 1 d after ischemia points to reactive changes in resistant brain areas.
...
PMID:Differential changes of bax, caspase-3 and p21 mRNA expression after transient focal brain ischemia in the rat. 1092 46
The thermodynamic stability and oligomerization status of the
tumor suppressor p53
tetramerization domain have been studied experimentally and theoretically. A series of hydrophilic mutations at Met-340 and Leu-344 of human
p53
were designed to disrupt the hydrophobic dimer-dimer interface of the tetrameric oligomerization domain of
p53
(residues 325-355). Meanfield calculations of the free energy of the solvated mutants as a function of interdimer distance were compared with experimental data on the thermal stability and oligomeric state (tetramer, dimer, or equilibrium mixture of both) of each mutant. The calculations predicted a decreasing stability and oligomeric state for the following amino acids at residue 340: Met (tetramer) > Ser Asp, His, Gln, > Glu,
Lys
(dimer), whereas the experimental results showed the following order: Met (tetramer) > Ser > Gln > His,
Lys
> Asp, Glu (dimers). For residue 344, the calculated trend was Leu (tetramer) > Ala > Arg, Gln,
Lys
(dimer), and the experimental trend was Leu (tetramer) > Ala, Arg, Gln,
Lys
(dimer). The discrepancy for the
lysine
side chain at residue 340 is attributed to the dual nature of
lysine
, both hydrophobic and charged. The incorrect prediction of stability of the mutant with Asp at residue 340 is attributed to the fact that within the meanfield approach, we use the wild-type backbone configuration for all mutants, but low melting temperatures suggest a softening of the alpha-helices at the dimer-dimer interface. Overall, this initial application of meanfield theory toward a protein-solvent system is encouraging for the application of the theoretical model to more complex systems.
...
PMID:A meanfield approach to the thermodynamics of a protein-solvent system with application to the oligomerization of the tumor suppressor p53. 1094 84
The
p53 tumor suppressor protein
functions as a transcription factor. It has, however, been previously reported that some
p53
mutants are able to suppress cell growth independent of their transcriptional activity [Kaneuchi et al., (1999)]. In order to investigate the correlations between the trans-activation and growth-suppressive functions of
p53
, we have analyzed five
p53
mutants by CAT reporter assay, colony formation assay, and growth-rate analysis. Five
p53
mutants [Oh et al., (2000)]--199stop (Gly-->stop), 240ile (Ser-->Ile), 250ala (Pro-->Ala), 285lys (Glu-->
Lys
), and 291asn (
Lys
-->Asn)--were cotransfected with a reporter construct containing a
p53
-responsive element and then tested for their trans-activational activity in
p53
-null Saos-2 cells. As a result of a change in the protein structure, trans-activational activity was negated in 199stop, 240ile, 285lys, and 291asn, while 250ala retained its activity. Colony formation assay revealed that mutants 240ile and 250ala retained their growth suppression, while 199stop, 285lys, and 291asn did not. To study the features of these proteins, a group of isogenic cell lines that express mutant forms of
p53
was generated from HeLa cells, and their growth rate was then examined: one group, containing 199stop, 285lys, and 291asn, showed a rapid growth rate, similar to that of the original HeLa cells; the other group, containing 240ile and 250ala, however, exhibited a slow growth rate. In conclusion, mutant p53 240ile, which completely lost its trans-activational activity, nevertheless continued to exhibit its growth-suppressive activity. Further work is required to understand how 240ile is involved in growth suppression.
...
PMID:The p53 mutation which abrogates trans-activation while maintaining its growth-suppression activity. 1098 34
The protein coding segment of the
TP53
genes from the glioma-derived cell lines M059J and M059K was sequenced. The sequences from both cell lines were identical over 5039 bp, including the gene segment containing exons 2 through 9, exon 10, and the proximal segment of exon 11. In both cells, the first nucleotide of codon 286 (GAA, Glu) is changed to an A (AAA,
Lys
). Comparison with the same
TP53
segment from the A549 human lung carcinoma cell line revealed several differences in intron sequence.
...
PMID:Human TP53 from the malignant glioma-derived cell lines M059J and M059K has a cancer-associated mutation in exon 8. 1293 31
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>